12:00 AM
 | 
May 20, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

SAR302503: Phase III data

Top-line data from the double-blind, international Phase III JAKARTA trial in 289 patients with intermediate-2 or high-risk PMF, PPV-MF or PET-MF showed that once-daily 400 and 500 mg doses of oral SAR302503 each met the primary endpoint of improving the proportion of patients with a >=35%...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >